Novel Fused Heterocycles as 5-HT2A Receptor Agonists for Treating Neurological Diseases, Namely, Depression, Anxiety, Substance Abuse, and Headaches

Provided herein are novel fused heterocycles as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating neurological diseases, namely depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.